ABSTRACT

The purpose of the Thoracic Society of Australia and New Zealand guidelines is to provide simple, practical evidence-based recommendations for the acute use of oxygen in adults in clinical practice. The intended users are all health professionals responsible for the administration and/or monitoring of oxygen therapy in the management of acute medical patients in the community and hospital settings (excluding perioperative and intensive care patients), those responsible for the training of such health professionals, and both public and private health care organizations that deliver oxygen therapy.

Key words: adult, guideline, hyperoxia, hypoxia, oxygen, oxygen inhalation therapy.

Abbreviations: ABG, arterial blood gas; BTS, British Thoracic Society; COPD, chronic obstructive pulmonary disease; FiO₂, fraction of inspired oxygen; HDU, high dependency unit; ICU, intensive care unit; NIV, non-invasive ventilation; PaCO₂, arterial partial pressure of carbon dioxide; PaO₂, arterial partial pressure of oxygen; PCO₂, partial pressure of carbon dioxide; SaO₂, arterial oxygen saturation (measured by arterial blood gas); SpO₂, arterial oxygen saturation (measured by pulse oximeter); TSANZ, Thoracic Society of Australia and New Zealand.
Grading
Grades of recommendation (Table 1) relate to the Australian National Health and Medical Research Council grading system based on level of evidence, consistency of that evidence, clinical impact, generalizability and applicability.3 For a full explanation of the recommendation grades, please go to https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf

Guideline Development Group
This group included representatives from a range of professions and disciplines relevant to the scope of the guidelines.

Peer review
The draft guidelines were peer-reviewed by the Australasian College for Emergency Medicine, the Australian and New Zealand College of Anaesthetists, the Australian College of Nursing Ltd, the Cardiac Society of Australia and New Zealand, the Australian and New Zealand Intensive Care Society, the Australian Physiotherapy Association, the Council of Ambulance Authorities Inc. and the Internal Medicine Society of Australia and New Zealand.

Presentation
The guidelines are presented in the format of key concepts, the recommendations with grades of evidence and practice points, and the background evidence on which the recommendations are based. Key recommendations are summarized in Table 2.

Dissemination plan
The guidelines will be sent to medical and nursing directors of hospitals, primary care organizations and ambulance services, and the deans of medical, physiotherapy and nursing schools in Australia and New Zealand.

Table 1 Grades of recommendations

<table>
<thead>
<tr>
<th>Grade of recommendation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Body of evidence can be trusted to guide practice</td>
</tr>
<tr>
<td>B</td>
<td>Body of evidence can be trusted to guide practice in most situations</td>
</tr>
<tr>
<td>C</td>
<td>Body of evidence provides some support for recommendation(s) but care should be taken in its application</td>
</tr>
<tr>
<td>D</td>
<td>Body of evidence is weak and recommendation must be applied with caution</td>
</tr>
</tbody>
</table>

Source: National Health and Medical Research Council.

Implementation
The implementation of these guidelines by organizations will require communication, education and training strategies, and an audit system for monitoring compliance within a designated timeframe.

Expiry date
2019.

CONCEPTS
1 Oxygen should be considered as a drug that is prescribed and administered for specific indications, with a documented target oxygen saturation range and with regular monitoring of the patient’s response.
2 Oxygen is prescribed for the relief of hypoxaemia, not breathlessness.
3 Hypoxaemia is both a marker of risk of a poor outcome due to the severity of the underlying disease(s) that has caused hypoxaemia, and an independent risk factor of poor outcome.
4 There are risks associated with both hypoxaemia and hyperoxaemia, which underlie the importance of prescribing oxygen only if required, and to within a target oxygen saturation range.
5 The ‘swimming between the flags’ concept of titrating oxygen therapy, to within a specific target oxygen saturation range applies to a wide range of clinical situations, in addition to exacerbations of chronic obstructive pulmonary disease (COPD).
6 The variable accuracy of pulse oximetry in the estimation of arterial oxygen saturation (SaO2) represents the major limitation in its use to guide the titration of oxygen therapy.
7 The use of high concentration oxygen in a breathless patient in an attempt to protect against hypoxaemia in the event of a subsequent deterioration has the potential to cause delay in recognizing clinical deterioration and reduce the time available to initiate additional treatment.
8 If a patient who requires a high fraction of inspired oxygen (FiO2) to maintain adequate oxygen saturations deteriorates, there is limited opportunity to increase FiO2 to avoid life-threatening hypoxaemia. For this reason, patients who need high FiO2 should receive senior clinician review and transfer to an area where there are appropriate numbers of competent staff able to provide more intensive monitoring and therapy.
### Key recommendations

1. Pulse oximetry should be available in all clinical situations in which oxygen is used. [GRADE C]

2. ABG measurements should be considered in the following situations: [GRADE C]
   - Critically ill patients with cardiorespiratory or metabolic dysfunction
   - In patients with an SpO$_2$ of <92%
   - Deteriorating SpO$_2$ requiring increased FiO$_2$
   - Patients at risk of hypercapnia
   - Breathless patients in whom a reliable oximetry signal cannot be obtained.

3. Oxygen saturation measured by pulse oximetry should be considered a ‘vital sign’ and documented with other vital signs in patient assessment and management. [GRADE D]

4. An oxygen prescription should be documented in the patient records and drug chart. [GRADE D]

5. In COPD [GRADE B] and other conditions associated with chronic respiratory failure [GRADE C], oxygen should be administered if the SpO$_2$ is less than 88%, and titrated to a target SpO$_2$ range of 88–92%.

6. In other acute medical conditions, oxygen should be administered if the SpO$_2$ is less than 92%, and titrated to a target SpO$_2$ range of 92–96%. [GRADE C]

7. Patients who need an:
   - FiO$_2$ of $\geq 0.40$ (such as $\geq 6$ L/min via a simple face mask) to maintain an adequate SpO$_2$, should receive senior clinician review. [GRADE D]
   - FiO$_2$ of $\geq 0.50$ (such as $\geq 8$ L/min via a simple face mask) to maintain an adequate SpO$_2$, should be referred for ICU review. [GRADE D]

8. In COPD and other conditions associated with chronic respiratory failure the preferred method of bronchodilator administration is an air-driven nebulizer or metered dose inhaler +/- a spacer. [GRADE B]

9. For most patients standard nasal cannulae are the preferred method of oxygen delivery, with the flow rate varied to achieve the target oxygen saturation. [GRADE D]

10. In patients with hypercapnic respiratory failure (arterial pH of <7.35 and PaCO$_2$ of >45 mm Hg), NIV or invasive ventilation should be considered. [GRADE A] COPD patients with a pH of <7.26 managed with NIV require intensive monitoring with a low threshold for intubation.

11. It is recommended that patients receiving ventilatory support are located in an area, such as an HDU, ICU, a close observation unit or monitored bed unit, where there are adequate numbers of staff experienced in ventilatory support to provide an appropriate level of monitoring and titration of therapy. [GRADE D]

---

**ABG**, arterial blood gas; **COPD**, chronic obstructive pulmonary disease; **FiO$_2$**, fraction of inspired oxygen; **HDU**, high dependency unit; **ICU**, intensive care unit; **NIV**, non-invasive ventilation; **PaCO$_2$**, arterial partial pressure of carbon dioxide; **SpO$_2$**, arterial oxygen saturation measured by pulse oximeter.
be aware of the variable accuracy of SpO2 in the utilization of pulse oximetry in clinical practice. An SpO2 of ≥92% is a practical lower threshold to rule out hypoxaemia, defined as an SaO2 of <90%7 or an arterial partial pressure of oxygen (PaO2) of <60 mm Hg (8 kPa).5

2 Arterial blood gas (ABG) measurement should be considered in the following situations. [Grade C]
- Critically ill patients with cardiorespiratory or metabolic dysfunction
- In patients with an SpO2 of <92% in whom hypoxaemia may be present
- Deteriorating SpO2 requiring increased FiO2
- Patients at risk of hypercapnia
- Breathless patients in whom a reliable oximetry signal cannot be obtained.

Peripheral venous blood gas analysis is a less invasive test; however, it does not provide an accurate estimate of arterial partial pressure of carbon dioxide (PaCO2) or PaO2. It does, however, provide rapid clinically important information to assess acutely unwell patients, including pH, lactate, glucose, haemoglobin, sodium and potassium. In addition it provides a venous PCO2 which if less than 40 mm Hg, effectively rules out hypercapnia.10

Arterialized capillary earlobe or fingertip blood gas measurements represent an alternative if unable to obtain an ABG measurement, recognizing that while providing accurate information about PaCO2 and pH, they variably underestimate PaO2 measurements.11,12 As a result, patient assessment can be based on pH and partial pressure of carbon dioxide (PCO2) levels measured from earlobe or fingertip blood gases, together with SpO2 by pulse oximetry. [Practice point: Hypoxaemia requires investigation and treatment of the underlying cause, and consideration of the contribution of hypoventilation, including measurement of PaCO2 and pH.]

Prescription
1 A specific oxygen prescription should be documented in the patient records and the drug chart.13 [Grade D]

[Practice point: The main requirement for an oxygen prescription is documentation of the target SpO2 range.

In its most detailed form, the prescription could include the delivery system and interface, the target oxygen saturation range, the range of flow rates for each delivery system, and instruction as to SpO2 and FiO2 at which clinical review should be sought. Considerable space on the prescription form is needed to provide such detail.

Oxygen administration (see Fig. 1)
1 An SpO2 target of 88–92% is recommended in exacerbations of COPD14 [Grade B] and other conditions associated with chronic respiratory failure (such as obesity hypoventilation syndrome,15 bronchiectasis, cystic fibrosis,16 neuromuscular disease and chest wall deformities such as severe kyphoscoliosis). [Grade C]

Practice points: Where there is diagnostic uncertainty as to whether COPD is the primary cause of the exacerbation, it may be preferable to titrate oxygen therapy to the 88–92% SpO2 target range.4,11,19

If the patient is breathing room air and has a saturation of ≥88%, then the initiation of oxygen is not routinely required and may result in oxygen saturations outside the target saturation range.

2 In the presence of hypoxaemia in other acute medical conditions, oxygen should be administered to achieve a target SpO2 range of 92–96%.20,21 [Grade C]

[Practice point: If the patient is breathing room air and has a saturation of ≥92%, then the initiation of oxygen is not routinely required and may place the patient at risk of oxygen saturations outside the target saturation range.

3 A target of around 85% is recommended in patients previously exposed to bleomycin or in paraquat poisoning.22–24 [Grade B]

4 Patients with carbon monoxide poisoning should receive normobaric hyperoxia or hyperbaric oxygen therapy.25,26 [Grade B] Note that pulse oximetry is likely to be inaccurate in this setting.

[Practice point: In the immediate assessment of an acutely unwell patient, oxygen saturations should be measured by oximetry, pending the availability of blood gas results if required (See Assessment, Point 2).

a. In the presence of COPD or conditions associated with chronic respiratory failure:
- If SpO2 ≥ 88%, oxygen therapy is not initially required.
- If SpO2 < 88%, oxygen can be administered at 1–2 L/min via nasal cannulae or 2–4 L/min via 24% or 28% Venturi mask, and titrated to achieve target SpO2.
- The avoidance of inappropriate high concentration oxygen therapy may be facilitated by the provision of a COPD oxygen alert card.27

b. In the absence of COPD or known chronic respiratory failure:
- If SpO2 ≥ 92%, oxygen therapy is not routinely required.
- If SpO2 is 85–91%, oxygen can be initially instilled at 2–4 L/min via nasal cannulae or other suitable oxygen delivery method, and titrated to achieve target SpO2. In many situations, this range of oxygen saturations is unlikely to be associated with risk, although oxygen is commonly administered.
- If SpO2 < 85%, oxygen can be initiated at 4 L/min via nasal cannulae, through a simple face mask at 5–10 L/min, a 100% non-rebreather reservoir mask at 15 L/min, or humidified high flow nasal cannulae (FiO2 > 0.35). The choice of delivery system will depend on the SpO2 level (higher FiO2 will be required with greater reductions in SpO2), and titrated to achieve the target SpO2 as soon as practically possible.

[Practice point: If oximetry is not available, or reliable SpO2 cannot be determined and hypoxaemia is suspected, oxygen can be delivered at:
- 1–2 L/min via nasal cannulae or 2–4 L/min via 24% or 28% Venturi mask in patients with acute exacerb-
Treatment algorithm for oxygen therapy. Please refer to the text for full recommendations, references and evidence grading. *Such as COPD, obesity hypoventilation syndrome, chest wall deformities, cystic fibrosis, bronchiectasis or neuromuscular disease. †If oximetry is not available, or reliable oxygen saturations cannot be determined and hypoxaemia is suspected, oxygen can be delivered at:
- 1–2 L/min via nasal cannulae or 2–4 L/min via 24% or 28% Venturi mask
- Titrate O2 to achieve SpO2 88–92% target range
- Give bronchodilator (if required) by air-driven nebuliser or MDI
- Obtain ABG

- pH <7.35 and PaCO2 >45 mm Hg
- SpO2 <88%
  - Start O2 1–2 L/min nasal cannulae or 2–4 L/min via 24% or 28% Venturi mask
  - Titrate O2 to achieve SpO2 88–92% target range
  - Give bronchodilator (if required) by air-driven nebuliser or MDI
  - Obtain ABG

- pH >7.35
- SpO2 ≥88%
  - No O2 therapy
  - Continue monitoring
  - Consider ABG

- PaCO2 >45 mm Hg or PaO2 <60 mm Hg (despite high flow O2 via mask)
- SpO2 <88%
  - Consider NIV or invasive ventilation and/or ICU/HDU admission
  - O2 as needed to maintain SpO2 88–92% target range

- PaCO2 <45 mm Hg and PaO2 ≥60 mm Hg
- SpO2 ≥92%
  - O2 not routinely required
  - Continue monitoring SpO2

- SpO2 85–91%
  - Start O2 4 L/min nasal cannulae, 5–10 L/min via mask, 15 L/min via a 100% non-rebreather reservoir mask or HFNC (FiO2 > 0.33) depending on clinical situation
  - Titrate O2 to achieve SpO2 92–96% target range
  - Obtain ABG

- SpO2 ≥ 92%
  - Monitor SpO2
  - Titrate O2 to maintain SpO2 92–96%

- SpO2 85–91%
  - Start 2–4 L/min nasal cannulae or other suitable oxygen delivery method
  - Titrate O2 to achieve SpO2 92–96% target range
  - Consider ABG

- SpO2 <92%
  - Consider NIV or invasive ventilation and/or ICU/HDU admission
  - O2 as needed to maintain SpO2 88–92% target range

- SpO2 ≥92%
  - O2 not routinely required
  - Continue monitoring SpO2

**Practice point:** As hypoxaemia is a risk factor for poor clinical outcomes, 28 SpO2 is a ‘vital sign’, to be considered together with other signs, including respiratory rate, which is a predictor of potentially serious clinical events. 29 [Grade D]

The New South Wales Standard Adult Observation Chart provides a practical example of the documentation of SpO2 as one of the vital signs and a designated level for clinical review and rapid response. (http://nswhealth.moodle.com.au/DOH/DETECT/content/00_worry/when_to_worry_07.htm).

3 Patients who need an estimated FiO2 of ≥0.40, such as ≥6 L/min via a simple face mask, to maintain an adequate SpO2 should receive senior clinician review and may require transfer to a facility such as a high dependency unit (HDU), where there are appropriate numbers of competent staff able to provide more intensive monitoring and therapy. [Grade D]
4 Patients who need an estimated FiO₂ of ≥0.50, such as ≥8 L/min via a simple face mask, to maintain an adequate SpO₂, should receive intensive care unit (ICU) review and most will require ICU transfer. [Grade D]

Practice point: In patients whose oxygen saturations improve with oxygen therapy to above the target oxygen saturation range, their inspired oxygen therapy can be reduced or stopped. Oxygen saturation monitoring would continue to allow the detection of any subsequent deterioration of the underlying condition and the requirement to increase or resume oxygen therapy.

A reduction in SpO₂ while the FiO₂ is maintained, or increasing FiO₂ requirements to maintain SpO₂, should lead to a further assessment of the patient.

Delivery system
1 For most patients standard nasal cannulae are the preferred method of oxygen delivery, with the flow rate varied to achieve the target oxygen saturation. [Grade D]
2 The FiO₂ levels delivered by the different delivery systems may vary considerably between patients and be influenced by a number of factors, including respiratory rate and whether the patient’s mouth is open or closed.30–37 Approximate FiO₂ values delivered by different delivery systems are:
   • Standard nasal cannulae can deliver an FiO₂ of 0.24–0.35 at an oxygen flow of 1–4 L/min
   • Venturi masks can deliver an FiO₂ of 0.24–0.60
   • High flow nasal cannulae can deliver an FiO₂ of 0.21–0.80
   • A simple face mask can deliver an FiO₂ of 0.35–0.60 at an oxygen flow of 5–10 L/min
   • A 100% non-rebreather reservoir mask at 15 L/min can deliver an FiO₂ of >0.60
3 For simple face masks, flow rates of <5 L/min should be avoided due to the potential risk of carbon dioxide rebreathing.38,39 [Grade C]
4 Humidification of oxygen via high flow nasal cannulae may improve comfort and tolerance.40,41

Bronchodilator administration
1 In COPD and other conditions associated with chronic respiratory failure, if a bronchodilator is required, the preferred methods of administration are via an air-driven nebulizer or via a metered dose inhaler +/− a spacer, with supplemental nasal oxygen continued as required.14,42 [Grade B]

Practice point: The administration of bronchodilator via an oxygen-driven nebulizer has the potential to cause an increase in PaCO₂.13,44 It has been recommended that if an oxygen-driven nebulizer is used in a patient with an exacerbation of COPD, then its use is limited to 6 min.1
2 In asthma, if a bronchodilator is required, methods of delivery include an oxygen or air-driven nebulizer or metered dose inhaler +/− a spacer.45

Positioning
1 Fully conscious hypoxaemic patients should be allowed to position themselves according to their preference and comfort. [Grade D] In some, but not all patients, upright posture may result in improved oxygenation.46–48

Ventilatory support
1 In patients with hypercapnic respiratory failure, in whom an ABG measurement shows a pH of <7.35 and PaCO₂ of >45 mm Hg, non-invasive ventilation (NIV) or invasive ventilation should be considered.49–53 [Grade A]
2 In patients in whom oxygen-induced hypercapnia is suspected, oxygen therapy should be titrated to maintain the 88–92% target oxygen saturation range and not be abruptly stopped due to the risk of profound rebound hypoxaemia.54–56 [Grade C]
3 In patients with severe cardiogenic pulmonary oedema continuous positive airway pressure should be considered.57 [Grade A]
4 NIV is not routinely recommended in acute hypoxaemic respiratory failure, as results from clinical trials and observational studies have provided mixed results for various patient groups50,58–61; however, there is some evidence of benefit in certain patients with immunosuppression.50,58,60,62–63 [Grade C]
5 It is recommended that patients receiving ventilatory support are located in a ward area such as an HDU, ICU, a close observation unit or monitored bed unit, where there are adequate numbers of staff experienced in ventilatory support to provide an appropriate level of monitoring and titration of therapy.63 [Grade D]

BACKGROUND EVIDENCE
1 Oxygen therapy does not relieve breathlessness in the absence of hypoxaemia. For example, there is no clinical benefit with short burst oxygen therapy in COPD patients with breathlessness,64 or with the use of oxygen over room air via nasal cannulae for patients with COPD who do not have severe resting hypoxaemia.65 Similarly, there is no additional symptomatic benefit in the use of oxygen over room air via nasal cannulae for refractory breathlessness in the palliative setting.66

In the absence of hypoxaemia, oxygen therapy is not indicated in the treatment of acute coronary syndrome or stroke, conditions associated with reversible ischaemia. In myocardial infarction, high concentration oxygen therapy is associated with greater infarct size, when compared with room air or titrated oxygen therapy if required to avoid hypoxaemia.67,68 In stroke, routine administration of continuous or nocturnal oxygen therapy does not improve outcomes.69,70
2 Hypoxaemia is both a marker of risk of a poor outcome due to the severity of the underlying disease(s) that has caused hypoxaemia, and an independent risk factor of poor outcome.28,71 The clinical impact depends on the underlying cause(s), the speed of onset and severity of hypoxaemia, the age of the
patient and associated co-morbidities. It has been proposed that an PaO2 of 50 mm Hg (6.6 kPa) can be considered as the safe lower limit of hypoxaemia in patients with COPD, and that oxygen therapy that achieves an PaO2 of at least 50 mm Hg would prevent immediate death from hypoxaemia.

The potential risks due to hyperoxaemia with high concentration oxygen therapy include respiratory (increased PaCO2, absorption atelectasis and direct pulmonary toxicity), cardiovascular (increased systemic vascular resistance and blood pressure, reduced coronary artery blood flow, reduced cardiac output), cerebrovascular (reduced cerebral blood flow) effects and increased reperfusion injury due to increased reactive oxygen species.

The physiological response of an increase in PaCO2 due to high concentration oxygen therapy has been demonstrated not only in stable and acute exacerbations of COPD, but also in severe asthma and community-acquired pneumonia and obesity hypoventilation syndrome. Proposed mechanisms for oxygen-induced hypercapnia include increased ventilation perfusion mismatch due to reduced hypoxic pulmonary vasoconstriction, reduced ventilatory drive, atelectasis and the Haldane effect, with the contribution of each likely to depend on the clinical situation.

There is variable accuracy of pulse oximetry to predict SaO2 in acutely ill patients, with SpO2 measurements both over and under estimating SaO2, with wide limits of agreement. Clinicians need to be aware of the variable accuracy of SpO2 in the utilization of pulse oximetry in clinical practice. Factors that might affect the accuracy of pulse oximetry include severe hypoxaemia, carboxyhaemoglobin and methaemoglobin levels, anaemia, dark skin, low perfusion, excessive ambient light and nail polish.

The use of high flow oxygen in an attempt to protect against subsequent hypoxaemia in the event of deterioration has the potential to delay the recognition of such a deterioration. This may provide a false reassurance that the patient is stable. There is likely to be no major change in vital signs or a marked decrease in SpO2 as assessed by pulse oximetry until a potentially life-threatening situation has developed. At this stage there is limited opportunity to further increase the oxygen therapy while medical review and an intervention such as transfer to an HDU or ICU is undertaken.

Similarly, if a patient who requires a high FiO2 to maintain adequate SpO2 deteriorates there is limited capacity to increase FiO2 to avoid life-threatening hypoxaemia. For this reason it is recommended that patients who need an FiO2 of ≥0.40, such as ≥6 Litres per minute via a simple face mask, to maintain an adequate SpO2, should receive senior clinician review and may require transfer to a ward area, such as an HDU. Likewise, patients who need an FiO2 ≥0.50, such as ≥8 L/min via a simple face mask, to maintain an adequate SpO2, should receive ICU review as most will require ICU transfer.

Peripheral venous blood gas analysis is a less invasive test than an ABG; however, it does not provide an accurate estimate of PaCO2 or PaO2. It does, however, provide rapid clinically important information to assess acutely unwell patients, including pH, lactate, glucose, haemoglobin, sodium and potassium. In addition it provides a PCO2 that, if less than 40 mm Hg, essentially rules out hypercapnia. A systematic review and meta-analysis has compared venous and ABG measurements. The point estimate for the difference between PaCO2 and venous PCO2 was 4.1 mm Hg higher for the venous reading, but with wide 95% confidence limits from 10.7 mm Hg higher to 2.4 mm Hg lower. PaO2 was higher than venous PO2 by 36.9 mm Hg with a 95% confidence interval of 27.2–46.6 mm Hg. Arterial pH values were slightly higher than venous pH; 0.03 with a 95% confidence interval of 0.029–0.038.

A target SpO2 range of 88–92% is recommended in the treatment of COPD and other conditions associated with chronic respiratory failure due to demonstration of:

- A greater than twofold reduction in mortality with pre-hospital oxygen therapy titrated to this target, compared with high concentration oxygen therapy in patients with an acute exacerbation of COPD.
- An increase in PaCO2 with 100% oxygen therapy in patients with chronic respiratory failure due to obesity hypoventilation syndrome.

A general target SpO2 range of 92–96% is recommended in acute medical conditions has been recommended, incorporating a lower range than that recommended in the BTS guidelines (94–98%). This lower target recognises that:

- An SpO2 of ≥92% is a practical lower threshold to rule out hypoxaemia, defined as an SaO2 of <90% or an PaO2 of <60 mm Hg (8 kPa).
- There is no known risk of hypoxic tissue injury at an SaO2 of 90%.
- Older healthy subjects have SaO2 levels to this lower level of 90%.
- Healthy subjects have a mean nadir SpO2 of around 90% during sleep.
- Subjects with sleep-disordered breathing commonly tolerate SpO2 levels between 80% and 90% for prolonged periods.
- Adults with co-morbidities tolerate SpO2 levels between 80% and 90% during long distance travel.
- Guidelines for acute coronary syndrome and heart failure recommend administration of oxygen if the SpO2 is <93% and <90%, respectively.
- In adults with coronary artery disease, anaerobic metabolism indicative of myocardial ischaemia is observed in some patients with SaO2 between 70% and 85%, suggesting a ‘safe’ lower limit of oxygen saturation of 90%.
- There is an evidence base for titration of oxygen therapy to a target SpO2 range of 93–95% in acute severe asthma and community-acquired pneumonia.
- There is an evidence base for the safety of oxygen therapy to a target SpO2 range of 88–92% in acute exacerbations of COPD.
• This recommendation is likely to reduce excessive use of high concentration oxygen therapy.
• An upper level of 96% avoids the potential risks of hyperoxia and allows for patient improvement to be recognized earlier during monitoring, so that oxygen can be down-titrated.

10 A target Spo2 range of 85% is recommended in patients with prior exposure to bleomycin or in paraquat poisoning due to the demonstration of:
• Potentiation of lung injury by oxygen22,23
• Lack of harm from hypoxaemia with saturations around 85% in these clinical situations24

11 The potential advantages of nasal cannulae as an initial method of delivering oxygen therapy are:
• Ability to give nebulized bronchodilator at the same time as oxygen is administered.
• Oxygen can be prescribed by variable flows to achieve a target saturation range rather than a fixed FiO2, although oxygenation may be maintained better with a Venturi mask.32
• Comfort, ease of use and low cost.
• Less likely to be taken off to eat or speak, and less likely to fall off.
• No risk of rebreathing of carbon dioxide.

12 Humidified high flow nasal cannulae are an alternative to standard low flow nasal cannulae or high flow masks for oxygen delivery.3,4,10,11,12 There are no published evidence-based guidelines for their clinical use in adults; however, currently, some centres recommend high flow nasal cannulae only in the emergency department, HDU or ICU. The potential advantages, demonstrated mostly from observational studies, of this delivery system include:
• Greater comfort and tolerance via delivery of warmed and humidified nasal oxygen, compared with delivery via a face mask.
• Better titration of FiO2 across a wider range of FiO2.
• Preservation of upper airways function, such as speech, swallowing and cough.
Potential disadvantages of high flow nasal cannulae include:
• Risk of complacency if a high FiO2 requirement is not recognized to represent life-threatening illness requiring more than correction of hypoxaemia.
• Role in severe exacerbations of COPD and asthma has not been investigated.

Acknowledgements
The authors would like to recognize the contribution of Dr Jeff Presto in bringing this Guideline Group together, in his capacity as Chair of the Physiology and Sleep Special Interest Group of the TSANZ before his untimely passing on 7 March 2014.

REFERENCES


**Respirology**

<table>
<thead>
<tr>
<th>Basic Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
</tr>
<tr>
<td><strong>ISSN</strong></td>
</tr>
<tr>
<td><strong>Publisher</strong></td>
</tr>
<tr>
<td><strong>Country</strong></td>
</tr>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Start Year</strong></td>
</tr>
<tr>
<td><strong>Frequency</strong></td>
</tr>
<tr>
<td><strong>Language of Text</strong></td>
</tr>
<tr>
<td><strong>Refereed</strong></td>
</tr>
<tr>
<td><strong>Abstracted / Indexed</strong></td>
</tr>
<tr>
<td><strong>Serial Type</strong></td>
</tr>
<tr>
<td><strong>Content Type</strong></td>
</tr>
<tr>
<td><strong>Format</strong></td>
</tr>
<tr>
<td><strong>Email</strong></td>
</tr>
</tbody>
</table>

**Description**
Publishes articles of scientific excellence in clinical and experimental respiratory biology and disease, and related fields of research.

**Related Titles**
- Alternative Media Edition (1)

**Lists**
- Marked Titles (0)

**Search History**
- 1323-7799 - (1)